Ncd Immunomedicare Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-07-2024
- Paid Up Capital ₹ 0.14 M
as on 08-07-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 08-07-2024
- Revenue 52.92%
(FY 2022)
- Profit 123.29%
(FY 2022)
- Ebitda 70.49%
(FY 2022)
- Net Worth 27.55%
(FY 2022)
- Total Assets 18.78%
(FY 2022)
About Ncd Immunomedicare
The Corporate was formerly known as N.C. Das Immunomedicare Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.14 M.
The company currently has active open charges totaling ₹5.00 M.
Rishav Das, Sandip Goswami, Saibal Moitra, and Two other members serve as directors at the Company.
- CIN/LLPIN
U33110WB2010PTC145296
- Company No.
145296
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Apr 2010
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ncd Immunomedicare?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayati Das  | Director | 16-Apr-2010 | Current |
| Rishav Das | Director | 21-Jan-2017 | Current |
| Sandip Goswami | Director | 18-Mar-2016 | Current |
| Saibal Moitra | Director | 08-Nov-2012 | Current |
| Arijit Das | Director | 16-Apr-2010 | Current |
Financial Performance of Ncd Immunomedicare.
Ncd Immunomedicare Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 52.92% increase. The company also saw a substantial improvement in profitability, with a 123.29% increase in profit. The company's net worth Soared by an impressive increase of 27.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ncd Immunomedicare?
In 2022, Ncd Immunomedicare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ncd Immuno-Pharma Private LimitedActive 2 years 9 monthsSandip Goswami and Arijit Das are mutual person
- Aerus Speciality Clinic & Diagnostics Private LimitedActive 2 years 9 months
Sandip Goswami and Arijit Das are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 14 Jun 2022 | ₹5.00 M | Open |
How Many Employees Work at Ncd Immunomedicare?
Unlock and access historical data on people associated with Ncd Immunomedicare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ncd Immunomedicare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ncd Immunomedicare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
